Skip to main content

Clinical Trials Using Therapeutic Allogeneic Lymphocytes

Review the clinical trials studying therapeutic allogeneic lymphocytes on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 108

Donor CD30.CAR-EBVST in Patients with Relapsed or Refractory CD-30 Positive Lymphomas
Status: Active
Location: 3 locations
Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma
Status: Active
Location: 3 locations
Immunosuppression-Free Regulatory T Cell Graft-Engineered Haploidentical Donor Stem Cell Transplant for the Treatment of Relapsed/Refractory or Ultra High Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 3 locations
CD5.CAR/28 T Cells, Cyclophosphamide, and Fludarabine in Treating Participants with Recurrent T-Cell Malignancies Expressing the CD5 Antigen
Status: Active
Location: 3 locations
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Status: Active
Location: 2 locations
PD-L1 t-haNK with N-803 and Cetuximab for the Treatment of Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
Status: Active
Location: 2 locations
Viral Specific T Cells for the Treatment of Adenovirus, Cytomegalovirus, or Epstein-Barr Virus Infection after Stem Cell or Solid Organ Transplantation and in Patients with Compromised Immunity
Status: Active
Location: 2 locations
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status: Active
Location: 3 locations
AD-PluReceptor NK Cells plus Tafasitamab-Cxix and Lymphodepleting Chemotherapy for the Treatment of Patients with Systemic Sclerosis or System Lupus Erythematosus
Status: Active
Location: 2 locations
T-allo10 Infusion Therapy to Prevent Graft Versus Host Disease and Improve Potential Immune Reconstitution in Patients who received Hematopoietic Stem Cell Transplantation
Status: Active
Location: 2 locations
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Status: Active
Location: 2 locations
Cytokine-Induced Memory-Like Natural Killer Cells and Interleukin-2 with Venetoclax as Consolidation Therapy for the Treatment of Acute Myeloid Leukemia
Status: Active
Location: 2 locations
CD4 Chimeric Antigen Receptor T Cell Therapy for Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia
Status: Active
Location: 3 locations
Cytokine-Induced Memory-Like Natural Killer Cell Therapy with interlekin-2 after Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with Measurable Residual Disease
Status: Active
Location: 2 locations
Cytokine-Induced Memory-Like Natural Killer Cell Therapy for the Treatment of Recurrent Ovarian Cancer
Status: Active
Location: 2 locations
Azacitidine, Venetoclax, and Donor-Derived Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia
Status: Active
Location: 2 locations
CD4CAR T Cell Therapy for the Treatment of Patients with Relapsed or Refractory CD4 Positive CMML
Status: Active
Location: 2 locations
Donor Immune Cells (Allogenic Ex Vivo Expanded Gamma Delta T Cells), Dinutuximab, Temozolomide, Irinotecan and Zoledronate for the Treatment of Refractory, Relapsed, or Progressive Neuroblastoma or Osteosarcoma in Children
Status: Active
Location: 2 locations
T Cells (EAGD T-Cells) after Stem Cell Transplantation and Post-transplant Cyclophosphamide for the Treatment of Blood Cancers
Status: Active
Location: 2 locations
Third Party Viral Specific T-cells (VSTs)
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Cytotoxic T Lymphocytes in Treating Patients with Malignancies with BK and/or JC Virus
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Specialized Stem Cell Transplant Product (CD34+ Selected Donor Cells) for the Treatment of Low Blood Counts after Donor Stem Cell Transplant
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Status: Active
Location: 2 locations
E7 TCR-T Cells with Aldesleukin for the Treatment of Recurrent/Refractory or Metastatic HPV-16 Positive Cancers
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey